Novo Nordisk (NVO) introduced a brand new $2.2 billion take care of San Francisco-based biotech Septerna (SEPN) for weight problems drugs — the newest in a sequence of strikes by
All posts tagged in licensing agreement
2Articles
Novo Nordisk (NVO) introduced a brand new $2.2 billion take care of San Francisco-based biotech Sapterna (SEPN) for weight problems tablets — the newest in a sequence of strikes by
Advertisement
